Zymeworks Rallies 30% On Positive Phase 3 Results For Ziihera In First-Line GEA

Zymeworks shares jumped 30.02% to $24.08 on heavy volume after positive topline Phase 3 HERIZON-GEA-01 results showed Ziihera (zanidatamab-hrii) plus chemotherapy significantly improved progression-free survival versus trastuzumab plus chemotherapy, and the triplet arm adding tislelizumab produced statistically significant improvements in both overall survival and PFS. Partner Jazz Pharmaceuticals plans to file a supplemental BLA in the first half of 2026 and Zymeworks expects the data to be presented at a major medical meeting in early 2026, highlighting clear regulatory and commercial implications for first-line HER2‑positive gastroesophageal adenocarcinoma. The stock now sits at the top of its 52-week range ($9.03–$24.08) following the announcement.

Analysis

Zymeworks shares jumped 30.02% to $24.08 (up $5.56) on heavy volume after positive topline Phase 3 HERIZON-GEA-01 results showed Ziihera (zanidatamab-hrii) plus chemotherapy significantly improved progression-free survival versus trastuzumab plus chemotherapy, and the triplet arm adding tislelizumab produced statistically significant improvements in both overall survival and PFS. The announcement triggered a notable intraday volume spike and pushed the stock to the top of its 52-week range ($9.03–$24.08), reflecting immediate re-pricing of the clinical and regulatory outlook. Partner Jazz Pharmaceuticals plans a supplemental Biologics License Application filing in the first half of 2026, and Zymeworks expects the data to be presented at a major medical meeting in early 2026, establishing a clear timeline of near- to mid-term catalysts. Key risks remaining are that these are topline results—full data, safety, subgroup analyses and regulator feedback are pending—and commercial and regulatory outcomes will depend on Jazz’s execution and the eventual label and payer acceptance.

Key Decisions for Investors

• Consider initiating a modest, risk-sized position to capture upside from the Phase 3 success and Jazz’s planned H1 2026 supplemental BLA while limiting exposure until full data are disclosed
• Defer material additions until the complete dataset and safety/subgroup analyses are presented at the planned early-2026 medical meeting, treating the topline readout as meaningful de-risking but not definitive
• If already long, consider trimming into strength given the 30% gap higher and the stock sitting at its 52-week high, and redeploy proceeds if/when more conservative entry points appear after post-catalyst volatility
• Monitor Jazz’s BLA submission timeline, regulatory interactions and the presentation date as primary execution catalysts and contemplate hedges (e.g., protective puts) ahead of those binary events